Skip to content

Study · Observational study · n = 205 · 2024

6 results

Efficacy and Safety of Injectable Dulaglutide 1.5 mg Among Type 2 Diabetes Patients in Clinics at King Saud Medical City, Riyadh, Saudi Arabia.

Albargawi MS, Alharbi RN, Alajlani MA, Abdulaal IA, Aldakhil LO

Journal of epidemiology and global health16 May 2024Cited by 3 (Europe PMC)

PMID38753098 (opens in a new tab)PMCIDPMC11442716 (opens in a new tab)DOI10.1007/s44197-024-00207-7 (opens in a new tab)PepBankPUB-38753098
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

IntroductionType 2 diabetes mellitus is the most common type of diabetes, characterized by varying degrees of insulin resistance and diminishing beta-cell function, which increases the risk of macrovascular and microvascular complications. Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist that is administered once weekly and approved for treating adults with type 2 diabetes mellitus. It can be used as a monotherapy or in addition to oral hypoglycemic or insulin therapy.AimThis study aims to provide information contributing to assessing the efficacy and safety of weekly 1.5 mg dulaglutide therapy in Saudi adult patients with type 2 diabetes mellitus.MethodsA retrospective single-arm cohort study using a purposive sample to recruit type 2 diabetes mellitus patients on dulaglutide from endocrine and diabetic outpatient clinics in King Saud Medical City (N = 205). Data were collected from participants' medical profiles and through the phone using interview questionnaires.ResultsMost participants were female and married; approximately 33% had had diabetes for more than 20 years, 41.4% of the sample had third-class obesity, and more than half had used dulaglutide for the last 1-2 years. With therapy, weight, body mass index, hemoglobin A1c, and fasting blood sugar were significantly improved after 6 and 12 months from baseline. The main side effects reported were nausea (52%) and fatigue (28%).ConclusionDulaglutide is a safe and effective therapy that demonstrated favorable glycemic control and weight reduction in obese type 2 diabetes patients of Saudi origin.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In Saudi adults with diabetes, dulaglutide use was linked to improved weight at both assessments versus baseline.

    In plain wordsIn Saudi adults with diabetes, dulaglutide use was linked to lower weight than baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight
    Study

    n = 205

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg weekly · 6 and 12 monthsAs given in this study (human).

    Source sentences

    Summary
    With therapy, weight, body mass index, hemoglobin A1c, and fasting blood sugar were significantly improved after 6 and 12 months from baseline.
    3 context sentences
    Summary · context
    Dulaglutide is a safe and effective therapy that demonstrated favorable glycemic control and weight reduction in obese type 2 diabetes patients of Saudi origin.
    Summary · context
    This study aims to provide information contributing to assessing the efficacy and safety of weekly 1.5 mg dulaglutide therapy in Saudi adult patients with type 2 diabetes mellitus.
    Summary · context
    A retrospective single-arm cohort study using a purposive sample to recruit type 2 diabetes mellitus patients on dulaglutide from endocrine and diabetic outpatient clinics in King Saud Medical City (N = 205).
  2. 02HumanObservational studyEfficacy outcome

    In Saudi adults with diabetes, dulaglutide use was linked to improved body mass index versus baseline.

    In plain wordsIn Saudi adults with diabetes, dulaglutide use was linked to improved body mass index versus baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody mass index
    Study

    n = 205

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg weekly · 6 and 12 monthsAs given in this study (human).

    Source sentences

    Summary
    With therapy, weight, body mass index, hemoglobin A1c, and fasting blood sugar were significantly improved after 6 and 12 months from baseline.
    2 context sentences
    Summary · context
    This study aims to provide information contributing to assessing the efficacy and safety of weekly 1.5 mg dulaglutide therapy in Saudi adult patients with type 2 diabetes mellitus.
    Summary · context
    A retrospective single-arm cohort study using a purposive sample to recruit type 2 diabetes mellitus patients on dulaglutide from endocrine and diabetic outpatient clinics in King Saud Medical City (N = 205).
  3. 03HumanObservational studyEfficacy outcome

    In Saudi adults with diabetes, dulaglutide use was linked to improved HbA1c versus baseline.

    In plain wordsIn Saudi adults with diabetes, dulaglutide use was linked to improved long-term blood sugar versus baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c
    Study

    n = 205

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg weekly · 6 and 12 monthsAs given in this study (human).

    Source sentences

    Summary
    With therapy, weight, body mass index, hemoglobin A1c, and fasting blood sugar were significantly improved after 6 and 12 months from baseline.
    2 context sentences
    Summary · context
    This study aims to provide information contributing to assessing the efficacy and safety of weekly 1.5 mg dulaglutide therapy in Saudi adult patients with type 2 diabetes mellitus.
    Summary · context
    A retrospective single-arm cohort study using a purposive sample to recruit type 2 diabetes mellitus patients on dulaglutide from endocrine and diabetic outpatient clinics in King Saud Medical City (N = 205).
  4. 04HumanObservational studyEfficacy outcome

    In Saudi adults with diabetes, dulaglutide use was linked to improved fasting blood sugar versus baseline.

    In plain wordsIn Saudi adults with diabetes, dulaglutide use was linked to improved fasting blood sugar versus baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting blood sugar
    Study

    n = 205

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg weekly · 6 and 12 monthsAs given in this study (human).

    Source sentences

    Summary
    With therapy, weight, body mass index, hemoglobin A1c, and fasting blood sugar were significantly improved after 6 and 12 months from baseline.
    2 context sentences
    Summary · context
    This study aims to provide information contributing to assessing the efficacy and safety of weekly 1.5 mg dulaglutide therapy in Saudi adult patients with type 2 diabetes mellitus.
    Summary · context
    A retrospective single-arm cohort study using a purposive sample to recruit type 2 diabetes mellitus patients on dulaglutide from endocrine and diabetic outpatient clinics in King Saud Medical City (N = 205).
  5. 05HumanObservational studySafety outcome

    In Saudi adults with diabetes using dulaglutide, nausea was reported in 52%.

    In plain wordsIn Saudi adults with diabetes using dulaglutide, 52% reported nausea.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNausea
    Study

    n = 205

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.5 mg weeklyAs given in this study (human).

    Measurements

    Nausea
    52%
    dulaglutide users

    Source sentences

    Summary
    The main side effects reported were nausea (52%) and fatigue (28%).
    2 context sentences
    Summary · context
    This study aims to provide information contributing to assessing the efficacy and safety of weekly 1.5 mg dulaglutide therapy in Saudi adult patients with type 2 diabetes mellitus.
    Summary · context
    A retrospective single-arm cohort study using a purposive sample to recruit type 2 diabetes mellitus patients on dulaglutide from endocrine and diabetic outpatient clinics in King Saud Medical City (N = 205).
  6. 06HumanObservational studySafety outcome

    In Saudi adults with diabetes using dulaglutide, fatigue was reported in 28%.

    In plain wordsIn Saudi adults with diabetes using dulaglutide, 28% reported fatigue.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableFatigue
    Study

    n = 205

    Outcome group
    Adverse events · Whole body
    Studied dose
    1.5 mg weeklyAs given in this study (human).

    Measurements

    Fatigue
    28%
    dulaglutide users

    Source sentences

    Summary
    The main side effects reported were nausea (52%) and fatigue (28%).
    2 context sentences
    Summary · context
    This study aims to provide information contributing to assessing the efficacy and safety of weekly 1.5 mg dulaglutide therapy in Saudi adult patients with type 2 diabetes mellitus.
    Summary · context
    A retrospective single-arm cohort study using a purposive sample to recruit type 2 diabetes mellitus patients on dulaglutide from endocrine and diabetic outpatient clinics in King Saud Medical City (N = 205).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.